Abbott Laboratories (ABT)

Business Overview

Abbott files a user count where Intuitive Surgical files a recurring share, and that count is the way into its consumables business. FY2025 net sales were $44,328M, the largest revenue base in this medtech set. Organic growth was 5.5%, or 6.7% excluding COVID-19 testing.

Abbott reports more than 8 million FreeStyle Libre users worldwide. Libre is its continuous glucose monitor (CGM), a wearable sensor that users replace on a cycle. Diabetes Care segment revenue was $7,998M (~$8.0B). The user base is the demand signal; sensor reorders show up in the Diabetes Care line, since there is no group recurring figure.

GAAP gross margin was 52.6%, the lowest of the six, because diagnostics and nutrition sit alongside devices. Abbott also charges $1,682M of amortisation of acquired intangibles above the gross line; before it the figure is 56.4%, the basis Medtronic, Stryker and Boston Scientific report on. The gross margin guide splits the gap by segment. GAAP operating margin was 18.2%. R&D was $2,942M, 6.6% of sales, the second lowest in the set after Stryker (6.5%).

How the Numbers Read

Organic growth (5.5%). Just above Medtronic (4.9% organic, year to 25 April 2025) and below the double-digit growers. Excluding COVID testing lifts it to 6.7%, because pandemic-era testing revenue still weighs on year-on-year comparisons in diagnostics.

Libre users (more than 8M) and Diabetes Care ($8.0B). The installed-base guide pairs Abbott's user count with Intuitive's 11,106 da Vinci systems, the only two group installed-base figures filed in this set. Abbott publishes no full-year CGM revenue; Q4 CGM sales were $2.0B. Four times that is a modelling shortcut; the disclosed figure is the $7,998M Diabetes Care line.

Free cash flow (~$7.4B). Operating cash flow of $9,566M less capex of $2,171M, from the 10-K; Abbott does not headline an FCF figure, unlike Boston Scientific's company-defined $3.7B (non-GAAP, 80% conversion).

Recurring mix, not filed. No group recurring or consumable share is filed. Libre users and Diabetes Care revenue are the proxies, and the recurring-mix screen (above 70% razor-blade, 40-70% hybrid, below 40% capital-cycle) cannot be applied. Intuitive Surgical's 84% is the only filed group share in the set.

Valuation Framework

Growth-adjusted P/E, forward P/E divided by organic growth, is the tool for comparing a 5.5% organic grower with companies whose growth runs at 15-21%; the growth-adjusted P/E guide works the method.

The input to settle first is how much of Diabetes Care growth comes from sensors. Libre user growth should feed recurring sensor revenue, but the segment also carries other diabetes products, so a forecast that treats all of Diabetes Care as CGM overstates the recurring part. Abbott's cardiovascular and structural-heart businesses follow the same procedure logic as Edwards' TAVR franchise, which the procedure volumes guide uses as its single-therapy case.

What to Watch in the Financials

Libre users against Diabetes Care revenue. The two should grow together. If they diverge, look for pricing pressure, a shift away from sensors or a geographic lag.

Organic growth ex COVID testing (6.7%). As testing comparisons roll off, organic growth converges on the ex-testing figure. Note which one management leads with in guidance.

Gross margin (52.6%). The lowest in the set. A rising CGM share should lift the group margin; if it does not, the diagnostics and nutrition mix is holding it down.

Key Risks

CGM competition. Libre's user base is a filed advantage. Rival sensor makers and their insurance coverage wins are the obvious threat to sensor reorders, and neither appears in Abbott's filings.

Breadth. Diagnostics, nutrition and established pharmaceuticals alongside devices lower the risk from any one product but hold group margins below Edwards (78.0% GAAP gross) or Boston Scientific (69.0%).

Disclosure. Without a group recurring share, CGM economics have to be inferred from segment data, and any change to segment reporting would break the series.

What the Screening Shows

Against the Medtech Sector Primer screens:

• Organic growth: 5.5% organic (6.7% ex COVID testing), mid single digits like Medtronic.
• Installed base: more than 8M Libre users, one of two group installed-base figures in the set (with Intuitive's da Vinci count).
• Diabetes Care: $7,998M segment revenue; not CGM only.
• Gross margin: 52.6% GAAP (56.4% before amortisation), lowest of the six.
• FCF: ~$7.4B (operating cash flow less capex).
• Recurring mix: not filed at group level.